Editas Medicine, Inc. (NASDAQ:EDIT) Stock Closed Above Its 50 …Modern ReadersCompany chares are trading at $20.09 which is slightly above $18.77, the 50 day moving average and which is just a bit higher than the 200 day moving …and more &… Continue reading
Editas Medicine, Inc. (NASDAQ:EDIT) Closed 7.0% Above Its 50 Day Moving AverageHighlight PressCRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either Cas9 (CRISPR associated protein 9) or Cpf1 (CRISPR from Prevotell… Continue reading
|
Cancer immunotherapy proves itself in earlier-stage disease
Reuters MADRID (Reuters) – Cancer doctors are widening the net for immunotherapy, a hot new class of drugs that enlist the body’s defenses in the fight against tumors. The latest research shared with 23,000 experts at Europe’s top oncology meeting shows how … |
|
Manchester Royal Eye Hospital delivers gene therapy for the first time
AOP Manchester Royal Eye Hospital (MREH) has delivered gene therapy for the first time as a treatment for X-linked retinitis pigmentosa (XLRP). The hospital is part of a ‘ground breaking’ pilot that involves more than 24 patients receiving a modified RPGR … |
New Atlas |
Changing a flower’s color with the CRISPR gene-editing tool
New Atlas It often takes years of careful cross-breeding for horticulturalists to turn flowers certain colors, but scientists can dig right in and change them at a genetic level much faster. Using the CRISPR-Cas9 gene-editing tool, scientists have changed the … |
|
CAR–T in the Courts
Genetic Engineering & Biotechnology News A patent fight continues over engineered chimeric antigen receptors for T–cell therapies (CAR-T). In December 2016, the Patent Trial and Appeal Board upheld a patent for a specific design of a chimeric antigen receptor (CAR) designed by researchers at … |
|
CAR–T in the Courts
Genetic Engineering & Biotechnology News A patent fight continues over engineered chimeric antigen receptors for T–cell therapies (CAR-T). In December 2016, the Patent Trial and Appeal Board upheld a patent for a specific design of a chimeric antigen receptor (CAR) designed by researchers at … |